AO-176
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity) . AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma[1][2][3][4].
Product Specifications
CAS Number
2691109-74-5
UNSPSC
12352203
Target
CD47
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19 (3) :835-846.|[2]Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206 (4) :712-721. |[3]William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1) : 3–4|[4]John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1) : 1844.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6245513-02 5x 0.1 mL
Prostate Cell Surface Antigen (MaxLight 490)
Sign In for Pricing
View Details 
orb2607042 100 µg
COX2/Cyclooxygenase 2/PTGS2 Rabbit Polyclonal Antibody (Cy3)
Sign In for Pricing
View Details